Academic History
Alex Rampotas, MD, PhD is an Academic Clinical Lecturer at the University College London (UCL) Cancer Institute, London, UK, specializing in Hematology.
He completed his medical degree at the Democritus University of Thrace, Komotini, Greece, followed by postgraduate Hematology training in the UK at Oxford and University College London Hospitals (UCLH). Dr Rampotas furthered his expertise with a postgraduate diploma in Health Research from the University of Oxford and a PhD focused on developing a novel CAR-T cell therapy for calreticulin-mutated myelofibrosis at UCL.
Dr Rampotas is an active member of the British Society for Haematology (BSH), the European Haematology Association (EHA), and the European Society for Blood and Marrow Transplantation (EBMT). His research primarily centers on cellular therapies and myeloproliferative neoplasms (MPNs), where he has conducted numerous real-world clinical studies. Recently, his translational work has advanced the development of an innovative CAR-T cell therapy for mutated calreticulin myelofibrosis. He is also involved in the Chronic Malignancies Working Party of the EBMT and participates actively as Early Career Researcher in the MPN Clinical Study Group in the UK.
Speaking on myeloproliferative neoplasms and CAR-T cell therapies
Dr Rampotas speaks on topics related to cellular therapies and MPNs, sharing his significant insights and research findings with the medical community. In particular, Dr Rampotas has a research focus on cellular therapies and novel immunotherapeutic approaches to tackle MPNs.
